This Top Non-Tech AI Trade for 2026 Pays a Huge 11.6% Dividend

The technology sector has experienced a remarkable rally in recent years, driven largely by advancements in artificial intelligence and other cutting-edge innovations. However, recent market trends suggest that this rally may be losing momentum. Investors with portfolios heavily concentrated in tech stocks might find it prudent to diversify into other sectors to manage risk and capture stable returns.

One compelling alternative gaining attention is the non-tech AI trade, particularly through funds and investments that focus on life sciences and large-cap companies outside the traditional tech giants. A notable example is the Abrdn Life Sciences Investors fund, which offers exposure to companies leveraging AI in healthcare and biotechnology. This fund stands out not only for its growth potential but also for its attractive dividend yield, which currently sits at an impressive 11.6%.

In addition to Abrdn, ETFs like the Roundhill Magnificent Seven ETF and the Defiance Large Cap ex-Mag 7 ETF provide diversified access to AI-driven companies beyond the core tech sector. The Roundhill Magnificent Seven ETF focuses on a select group of leading AI innovators, while the Defiance Large Cap ex-Mag 7 ETF excludes the seven largest tech companies, offering a broader market perspective. These funds help investors tap into AI's transformative impact across various industries without the concentrated risk of traditional tech stocks.

The shift toward non-tech AI investments is significant because it reflects a maturing market where AI applications are expanding into sectors like healthcare, manufacturing, and finance. These industries often provide more stable cash flows and dividends compared to the high-growth but volatile tech sector. As a result, investors seeking income and reduced volatility may find these non-tech AI trades particularly appealing.

Moreover, the high dividend yield of 11.6% offered by funds like Abrdn Life Sciences Investors is noteworthy in the current low-interest-rate environment. It provides an attractive income stream while still allowing investors to participate in the growth potential of AI-driven innovation. This combination of income and growth is rare and makes these funds a strategic addition to diversified portfolios.

In conclusion, as the tech rally shows signs of fading, shifting focus to non-tech AI investments can offer a balanced approach. Funds like Abrdn Life Sciences Investors and ETFs such as Roundhill Magnificent Seven and Defiance Large Cap ex-Mag 7 provide diversified exposure to AI's expanding influence with the added benefit of substantial dividend yields. This strategy helps investors manage risk while capitalizing on AI's broad market applications beyond traditional technology companies.